Title |
Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study
|
---|---|
Published in |
BMC Neurology, September 2016
|
DOI | 10.1186/s12883-016-0706-0 |
Pubmed ID | |
Authors |
Guro Berge, Sigrid B. Sando, Grethe Albrektsen, Camilla Lauridsen, Ina Møller, Gøril R. Grøntvedt, Geir Bråthen, Linda R. White |
Abstract |
α-Synuclein has been proposed as a potential biomarker for Alzheimer's disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) have been inconclusive, and to our knowledge, longitudinal studies of changes prior to the AD diagnosis have not been investigated. Levels of α-synuclein at baseline and after one and two years were measured in CSF, by enzyme-linked immunosorbent assay. Twenty-six patients with early AD (AD-AD), 48 patients with aMCI, subdivided as 23 that developed AD during follow-up (MCI-AD), and 25 that did not (MCI-MCI), and 25 healthy control individuals, were included. One-way ANOVA was applied to compare mean α-synuclein baseline values between all four study groups, and a linear mixed model was used to compare mean change over time between the three patient groups. Linear associations between α-synuclein and amyloid-β 1-42 (Aβ42), amyloid-β 1-40 (Aβ40), total tau and phosphorylated tau were also examined. A large variation in individual α-synuclein CSF levels was observed, particularly in the MCI-AD group. No significant differences were found in mean α-synuclein levels between all the study groups at baseline. When using a linear mixed model, no significant differences were found at follow-up for estimated mean changes between the patient groups. MCI-AD patients with short duration of symptoms prior to inclusion in the study (≤2 years) had considerably higher mean CSF α-synuclein levels compared to patients with a longer symptom duration (802.2 vs. 442.8 pg/mL, p = 0.01). No such difference was seen in the MCI-MCI or AD-AD groups. Significant linear associations (p < 0.0005) between α-synuclein and Aβ40, total tau and phosphorylated tau were found. The observed difference in mean CSF α-synuclein level according to duration of symptoms in the MCI-AD group, may be an indication of changes related to disease progression. However, the lack of significant differences between groups, as well as the large individual variation in CSF levels of α-synuclein in the present study, suggest that α-synuclein is not a useful biomarker for AD. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 42 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 8 | 19% |
Student > Ph. D. Student | 6 | 14% |
Researcher | 5 | 12% |
Student > Postgraduate | 4 | 10% |
Other | 3 | 7% |
Other | 6 | 14% |
Unknown | 10 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Neuroscience | 9 | 21% |
Medicine and Dentistry | 7 | 17% |
Biochemistry, Genetics and Molecular Biology | 5 | 12% |
Unspecified | 2 | 5% |
Psychology | 2 | 5% |
Other | 4 | 10% |
Unknown | 13 | 31% |